title: Cutaneous lupus erythematosus in a patient undergoing intravitreal bevacizumab injections: case report and review of the literature.
abstract: BACKGROUND
  Bevacizumab is a recombinant humanized antibody against vascular endothelial growth factor (VEGF). It is approved by the Food and Drug Administration (FDA) for metastatic colorectal cancer, advanced non-small cell lung cancer, metastatic renal cell cancer and glioblastoma. Bevacizumab has also been used off label in ophthalmology for age-related macular degeneration, diabetic retinopathy, retinal vein occlusions, retinopathy of prematurity, and other chorioretinal vascular disorders. Numerous case reports have described various cutaneous reactions in response to bevacizumab therapy including acneiform eruptions and exfoliative dermatitis.
  
  
  METHODS
  We report a case of a 63 year-old Caucasian female who presented with subacute cutaneous lupus erythematosus six weeks after initiating two intravitreal injections of bevacizumab for central serous choroidopathy.
  
  
  CONCLUSIONS
  We report the first documented case of a cutaneous lupus erythematosus eruption following bevacizumab administration as a monotherapy.
authors.forename: Nathan
authors.initials: N
authors.lastname: Cleaver
authors.forename: James
authors.initials: J
authors.lastname: Ramirez
authors.forename: Stuart
authors.initials: S
authors.lastname: Gildenberg
mesh_terms: D000287:Administration, Topical; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D000068258:Bevacizumab; D015862:Choroid Diseases / Q000150:complications* / Q000188:drug therapy*; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007267:Injections; D007642:Keratosis / Q000188:drug therapy / Q000473:pathology; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D056687:Off-Label Use; D012535:Scalp / Q000473:pathology; D012867:Skin / Q000473:pathology; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002990:Clobetasol